Breeding method for reducing or eliminating influence of exogenous gonadotropin on reproductive performance of female livestock
Through the combined use of N-acetylcysteine and vitamin A, the ERα-FGF-pERK-cell cycle signaling pathway was inhibited, and the uterine receptive damage and pregnancy rate reduction caused by exogenous gonadotropins was solved, and the females were improved Reproductive performance of livestock and the health of birth offspring.
Patent Information
- Application Number
- CN202410889342.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
After the use of exogenous gonadotropins in animal husbandry and assisted reproduction, it leads to a decrease in the uterine receptive damage and pregnancy rate of female domestic animals, and there is a lack of effective improvement measures.
Using the combination of N-acetylcysteine and vitamin A, the uterine receptivity and pregnancy outcome after treatment with exogenous gonadotropin are improved, and the embryo implantation rate is improved. , pregnancy rate and litter number.
Effectively reduce or exclude the impact of exogenous gonadotropins on the reproductive performance of female livestock, improve embryo implantation rate, pregnancy rate and litter count, and improve the health status of birth and offspring. It is suitable for the fields of animal husbandry and assisted reproduction.
Smart Images

Figure BDA0004927411480000161 
Figure BDA0004927411480000201 
Figure HDA0004927411650000011
Abstract
Description
Technical Field
[0001] The present invention relates to the biological field, and in particular to a breeding method for reducing or eliminating the influence of exogenous gonadotropin on the reproductive performance of female livestock. Background Art
[0002] Gonadotropins are glycoprotein hormones that regulate the development of mammalian gonads and gametes and promote the production and secretion of sex hormones. In the application of human assisted reproduction, exogenous follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG, used to replace luteinizing hormone LH to stimulate ovulation) are often used to induce superovulation in patients to obtain more eggs. In the livestock industry, due to cost and half-life considerations, equine chorionic gonadotropin (eCG) and gonadotropin-releasing hormone analogs (GnRH analogs, used to induce endogenous LH release) are usually selected to induce synchronous development of livestock follicles and ovulation at the same time to achieve intensive breeding management.
[0003] Although gonadotropin is an effective means of inducing ovulation in human assisted reproduction and livestock breeding management, it can not only increase the number of ovulations, but also more accurately control the time of ovulation, which is convenient for large-scale breeding management. However, for a long time, the use of exogenous gonadotropin has been faced with problems such as decreased pregnancy rate, embryo loss, and delayed fetal growth after implantation, and even miscarriage. For example, eCG / hCG superovulation treatment causes problems such as limited fetal growth and development after implantation in mice, increased fetal absorption rate, increased embryo loss rate in pregnant sows, and decreased clinical pregnancy rate in assisted reproduction. In response to the above problems, the existing technology has a certain improvement effect. For example, the existing public technology suggests that N-acetylcysteine can improve the pregnancy rate of in vitro fertilization-embryo transfer by relieving uterine contractions; in addition, N-acetylcysteine can improve the uterine environment and improve the ability of early embryo development, increase the number of implanted embryos, and have the ability to increase the number of litters in female livestock, or improve and improve the reproductive performance of female animals after applying timed insemination technology, effectively improve the breeding pregnancy rate of sows, etc. In addition, in the field of assisted reproduction, in order to reduce or eliminate the effects of exogenous gonadotropins on uterine receptivity and pregnancy outcomes, a frozen embryo transfer program is often used. That is, after women are treated with exogenous gonadotropins and have their eggs collected alive, the IVF embryos (fresh embryos) obtained are not directly transplanted, but the embryos are frozen and preserved. When the woman's uterus gradually recovers to a state without exogenous gonadotropin treatment, the frozen embryos are transplanted at an appropriate time to increase the pregnancy rate. However, embryo freezing has a certain impact on embryo development and the health of the offspring. For this reason, the field of assisted reproduction is also in urgent need of a method that can reduce or eliminate the effects of exogenous gonadotropins on uterine receptivity and pregnancy outcomes.
[0004] However, the causes and specific molecular regulatory mechanisms of gonadotropin-induced embryo loss, restricted fetal development after implantation, and decreased pregnancy rate have not been clear, so there has been a lack of measures to effectively improve uterine receptivity and pregnancy outcomes after exogenous gonadotropin treatment. Summary of the invention
[0005] The present invention aims to solve the technical problems existing in the prior art at least to a certain extent. To this end, the present invention proposes a breeding method for reducing or eliminating the influence of exogenous gonadotropins on the reproductive performance of female livestock and the use of a combination of N-acetylcysteine and vitamin A in the preparation of medicine or feed. The present invention can effectively reduce or eliminate the reproductive performance of female livestock after exogenous gonadotropin treatment, including its uterine receptivity and pregnancy outcomes, such as embryo implantation rate, fetal development status after implantation, pregnancy rate, litter size and health status of offspring born (liver metabolism, etc.), by combining N-acetylcysteine and vitamin A, and N-acetylcysteine and vitamin A have a synergistic effect, and have broad application prospects. For example, they can be used in animal husbandry to realize the regulation and management of livestock reproduction such as pigs, horses and cattle, and realize batch production. They can also be used in female assisted reproduction, and have high application value.
[0006] It should be noted that the present invention is completed based on the following findings of the inventors:
[0007] The inventors have found that exogenous gonadotropins can damage uterine receptivity during superovulation induction, and uterine receptivity damage is the main reason for decreased pregnancy rate and embryo loss after exogenous gonadotropin treatment. The inventors have found that exogenous gonadotropin treatment can cause endometrial ERα-FGF-pERK-cell cycle signaling pathway ( Figure 1 ) is overactivated. Further mechanism studies have found that exogenous gonadotropins can cause abnormally increased expression of estrogen receptor (ERa) in uterine cavity epithelial cells during the establishment of uterine receptivity, and abnormally increased expression of fibroblast growth factor (FGF) family members in stromal cells in the endometrium. Abnormally highly expressed FGF causes excessive phosphorylation and activation of the FGFR-ERK pathway in endometrial epithelial cells through paracrine effects, causing endometrial epithelial cells to continue to overproliferate, unable to establish uterine receptivity normally, and having an adverse effect on fetal development after implantation and growth at birth.
[0008] In view of this, since the abnormality of the ERα-FGF-pERK-cell cycle signaling pathway is the key signal for exogenous gonadotropin to induce decreased uterine receptivity, the inventors screened multiple targets of the signaling pathway. Specifically, the inventors tried a variety of inhibitory methods for this signaling pathway, but not all forms of inhibitory methods can achieve the expected effect. For example, when the inventors used BGJ398, an inhibitor of FGF receptors on the signaling pathway, to inhibit the signaling pathway, they found that although the number of implantation sites in the early pregnancy was significantly higher than that of the control group, it would have toxic side effects on fetal development in the late pregnancy, leading to abnormal development of the fetus after implantation.
[0009] Vitamin A (also referred to as "VA" in this article) is a fat-soluble vitamin. In the early 20th century, people first realized the need for vitamin A in animal reproduction and development, including the formation of germ cells, embryonic development and other processes. For example, when gilts lack vitamin A, it will lead to delayed estrus, and even if they are bred and conceived after estrus, it may cause miscarriage in the second trimester. There are public technical suggestions that injecting sows with vitamin A can increase the litter size. The close relationship between vitamin A and animal reproduction is mainly based on the fact that vitamin A can promote the synthesis of estrogen, thereby promoting follicle development and increasing the number of ovulations. People began to repeatedly use vitamin A for applied research on livestock reproduction regulation. However, there is no public data to suggest that vitamin A can be used to reduce or eliminate the decrease in uterine receptivity or pregnancy outcome after exogenous gonadotropin treatment.
[0010] Moreover, according to the provisions of Academician Li Defa and others in "Nutritional Requirements of Chinese Pigs" and "Nutritional Requirements of Pigs", the vitamin A requirement of lean gilts is 5000IU / kg, while the vitamin A requirement of fat gilts is 1700IU / kg. In comparison, the National Research Council (NRC) of the United States stipulates that the vitamin A requirement of gilts is 1300IU / kg. However, the inventors found through experiments that even if gilts are fed a diet that meets the above-mentioned vitamin A requirement, it is still difficult to effectively improve the problem of uterine receptivity damage and adverse pregnancy outcomes caused by exogenous gonadotropin treatment of gilts. This indicates that there may be other factors affecting the reproductive performance of gilts, and simply providing vitamin A cannot solve these problems. Therefore, further research and exploration of other possible nutritional factors or environmental factors are needed to better improve the reproductive performance of gilts.
[0011] N-acetylcysteine (also referred to as "NAC" in this article), with its chemical name N-acetyl-L-cysteine and molecular formula C5H9NO3S, has the functions of improving respiration, anti-oxidation, and enhancing the body's immunity. The inventors have found through a large number of experimental studies that N-acetylcysteine has a good inhibitory effect on the phosphorylation of endometrial ERK, and vitamin A can inhibit the expression of ERa. The combined use of the two has a better effect. In particular, it is found that by additionally applying nearly 100 times more vitamin A than the vitamin A content in conventional diets, it can achieve synergistic synergy with NAC, effectively inhibit the over-activation of the ERα-FGF-pERK-cell cycle signaling pathway, alleviate the abnormality of the ERα-FGF-pERK-cell cycle signaling pathway, and inhibit the excessive proliferation of endometrial epithelial cells, thereby improving uterine receptivity and pregnancy outcomes after exogenous gonadotropin treatment, such as improving embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size, etc., and it is not toxic to mammals, and can improve the reproductive performance of female animals as a whole, and has broad application prospects in the fields of assisted reproduction and livestock breeding. However, previous studies and existing technologies cannot suggest the application of N-acetylcysteine and vitamin A in reducing or eliminating the decrease in uterine receptivity and adverse pregnancy outcomes after exogenous gonadotropin treatment.
[0012] To this end, in one aspect of the present invention, the present invention proposes a breeding method for reducing or eliminating the effect of exogenous gonadotropins on the reproductive performance of female livestock. According to an embodiment of the present invention, the method comprises: before treating female livestock with exogenous gonadotropins, feeding the female livestock with N-acetylcysteine and vitamin A; after the feeding of N-acetylcysteine and vitamin A, the ERα-FGF-pERK-cell cycle signaling pathway of the female livestock is inhibited to improve the uterine receptivity and pregnancy outcome of the female livestock after the exogenous gonadotropin treatment; the mass ratio of N-acetylcysteine and vitamin A is 0.5:1 to 8:1; the dosage of N-acetylcysteine is 60 mg / Kg BW / day to 200 mg / Kg BW / day, and the dosage of vitamin A is 25 mg / Kg BW / day to 120 mg / Kg BW / day.
[0013] According to the method of the embodiment of the present invention, by using NAC and VA in combination, the over-activation of the ERα-FGF-pERK-cell cycle signaling pathway after exogenous gonadotropin treatment can be effectively inhibited, the effect of exogenous gonadotropin on the reproductive performance of female livestock can be reduced or eliminated, and the uterine receptivity and pregnancy outcomes, such as embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size, can be improved. Further, the inventors conducted in-depth research to obtain the mass ratio and respective dosage of NAC and VA, and especially found that by additionally applying nearly 100 times more vitamin A than the vitamin A content in conventional diets, it can achieve the purpose of synergistic enhancement with NAC, which can further and better improve the effect of exogenous gonadotropin on the reproductive performance of female livestock. The method of the present invention has a wide range of application prospects, for example, it can be used in animal husbandry to realize the regulation and management of livestock reproduction such as pigs, horses and cattle, and realize batch production, with high application value.
[0014] According to an embodiment of the present invention, the breeding method for reducing or eliminating the effect of exogenous gonadotropin on the reproductive performance of female livestock may also have the following additional technical features:
[0015] According to an embodiment of the present invention, oral administration of N-acetylcysteine and vitamin A begins 10 to 15 days before the treatment of female livestock with exogenous gonadotropins, and the administration is stopped at least until the first confirmation of pregnancy; or intraperitoneal administration of N-acetylcysteine and vitamin A begins 5 to 7 days before the treatment of female livestock with exogenous gonadotropins, and the administration is stopped at least until the first confirmation of pregnancy; or vaginal administration of N-acetylcysteine and vitamin A begins 3 to 4 days before the treatment of female livestock with exogenous gonadotropins, and the administration is stopped at least until the first confirmation of pregnancy.
[0016] According to an embodiment of the present invention, the female livestock is selected from a gilt or a multiparous sow; the exogenous gonadotropin includes at least one of the following: pregnant mare serum gonadotropin, equine chorionic gonadotropin, follicle-stimulating hormone, gonadotropin-releasing hormone and human chorionic gonadotropin.
[0017] According to an embodiment of the present invention, the improvement of uterine receptivity of female livestock after treatment with exogenous gonadotropins includes at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells; the pregnancy outcomes of female livestock after treatment with exogenous gonadotropins include at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size.
[0018] According to an embodiment of the present invention, the method comprises: subjecting the female livestock to sequential sexual cycle synchronization treatment, exogenous gonadotropin treatment, ovulation induction treatment and insemination treatment; and feeding N-acetylcysteine and vitamin A to the female livestock before the exogenous gonadotropin treatment.
[0019] According to an embodiment of the present invention, the sexual cycle synchronization treatment includes: feeding allylgestaltenes to gilts for 14 to 18 days or feeding synchronous weaning to multiparous sows, with a feeding amount of 15 mg to 25 mg / day; the exogenous gonadotropin treatment includes: injecting exogenous gonadotropins into the female livestock 1.5 to 2 days after the sexual cycle synchronization treatment; the ovulation induction treatment includes: injecting ovulation-promoting drugs into the female livestock treated with exogenous gonadotropins after an interval of 70 to 90 hours; the insemination treatment includes: performing the first insemination on the female livestock treated with ovulation induction after an interval of 20 to 28 hours, and then performing the second insemination after an interval of 14 to 16 hours.
[0020] In another aspect of the present invention, the present invention proposes a breeding method for reducing or eliminating the effect of exogenous gonadotropin on the reproductive performance of female livestock. According to an embodiment of the present invention, the method comprises: the gilts are orally administered with allylgestaol for 17 to 19 days, wherein 80 to 110 mg / kg BW of N-acetylcysteine and 80 to 110 mg / kg BW of vitamin A are added to the feed from the 5th to 7th day until the first pregnancy test is completed, and the mass ratio of N-acetylcysteine to vitamin A is 0.5:1 to 2:1; after stopping oral administration of allylgestaol, pregnant mare serum gonadotropin is injected at an interval of 41 to 43 hours to induce synchronization of follicular development; after the injection of pregnant mare serum gonadotropin, the ovulation-inducing drug gonadotropin is injected at an interval of 79 to 81 hours, and the first artificial insemination is performed at an interval of 23 to 25 hours after the injection, and the second artificial insemination is performed at an interval of 15 to 17 hours thereafter.
[0021] In another aspect of the present invention, the present invention proposes the use of a combination of N-acetylcysteine and vitamin A in the preparation of medicine or feed. According to an embodiment of the present invention, the medicine or feed is used to improve the reproductive performance of subjects after exogenous gonadotropin treatment, and is used to inhibit the ERα-FGF-pERK-cell cycle signaling pathway to improve the uterine receptivity, pregnancy outcome and health status of offspring after the exogenous gonadotropin treatment; the mass ratio of N-acetylcysteine and vitamin A is 0.5:1 to 8:1. Thus, the medicine or feed according to the embodiment of the present invention can effectively reduce or eliminate the effect of exogenous gonadotropin on the reproductive performance of female livestock, improve uterine receptivity and / or pregnancy outcome and / or health status of offspring after exogenous gonadotropin treatment, such as improving embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size, alleviating abnormal liver metabolism of offspring, etc., and overall improve the reproductive performance of female livestock, which has a wide range of application prospects.
[0022] According to an embodiment of the present invention, the improving the uterine receptivity of the subject after exogenous gonadotropin treatment comprises at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells;
[0023] The pregnancy outcomes of the subjects after the exogenous gonadotropin treatment include at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size;
[0024] The exogenous gonadotropin includes at least one of the following: pregnant mare serum gonadotropin, equine chorionic gonadotropin, follicle-stimulating hormone, gonadotropin-releasing hormone and human chorionic gonadotropin;
[0025] The administration methods of the N-acetylcysteine combined with vitamin A are independently selected from oral administration, intragastric administration, intraperitoneal injection, intravenous injection, intravenous drip, intramuscular or subcutaneous injection;
[0026] The dosage forms of the N-acetylcysteine combined with vitamin A are independently selected from oral liquid, injection, tablet, capsule, vaginal suppository or film.
[0027] In another aspect of the present invention, the present invention proposes an application of a combination of N-acetylcysteine and vitamin A in the preparation of a drug. According to an embodiment of the present invention, the drug is used for assisted reproduction, and is used to inhibit the ERα-FGF-pERK-cell cycle signaling pathway to improve the uterine receptivity, pregnancy outcome and health status of offspring after treatment with the exogenous gonadotropin; the mass ratio of N-acetylcysteine and vitamin A is 0.5:1 to 8:1. Therefore, the drug according to the embodiment of the present invention can effectively reduce or eliminate uterine receptivity and pregnancy outcomes after exogenous gonadotropin, such as improving embryo implantation rate, fetal development status after implantation, pregnancy rate and health status of offspring, etc., which is of great significance in assisted reproductive technology.
[0028] According to an embodiment of the present invention, the assisted reproduction is selected from fresh embryo transplantation.
[0029] According to an embodiment of the present invention, the improvement of uterine receptivity after gonadotropin treatment includes at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells;
[0030] The pregnancy outcomes after gonadotropin treatment include at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and number of offspring;
[0031] The administration methods of the N-acetylcysteine combined with vitamin A are independently selected from oral administration, intragastric administration, intraperitoneal injection, intravenous injection, intravenous drip, intramuscular or subcutaneous injection;
[0032] The dosage forms of the N-acetylcysteine combined with vitamin A are independently selected from oral liquid, injection, tablet, capsule, vaginal suppository or film.
[0033] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0035] Figure 1The molecular mechanism analysis diagram of exogenous gonadotropin affecting mouse uterine receptivity is shown. (A) Immunofluorescence results showed that the expression of estrogen receptor ERα increased significantly after gonadotropin treatment. (B) The mRNA level of endometrial FGF family genes increased after gonadotropin treatment. (C) Immunofluorescence and immunohistochemistry results showed that pFGFR2 and pERK were overexpressed in the endometrium; Ki67, a marker molecule for endometrial luminal epithelial proliferation, was overexpressed.
[0036] Figure 2 A schematic diagram of the timing of NAC and VA administration alone and in combination is shown.
[0037] Figure 3 The molecular mechanism analysis diagram of NAC and VA inhibiting the ERα-FGF-pERK-cell cycle signaling pathway and regulating the establishment of uterine receptivity is shown. (A) VA alone or NAC and VA combined administration can significantly inhibit the overexpression of ERα induced by exogenous gonadotropins; (B) and (C) NAC alone or NAC and VA combined administration can significantly inhibit the overexpression of pERK induced by exogenous gonadotropins; (D) NAC and VA regulatory pattern diagram of the ERα-FGF-pERK-cell cycle signaling pathway.
[0038] Figure 4 The analysis diagram of NAC and VA in alleviating the decreased embryo implantation and litter size induced by exogenous gonadotropin is shown. (A) NAC and VA combined in a specific ratio can significantly improve the decreased embryo implantation induced by exogenous gonadotropin. (B) NAC and VA combined in a specific ratio can significantly improve the decreased litter size induced by exogenous gonadotropin. (C) Fetal regression after BGJ398 treatment.
[0039] Figure 5 The analysis diagram of the effect of combined administration of NAC and VA on fresh embryo transfer is shown. (A) Grouping of frozen embryo transfer and fresh embryo transfer, the control group was transplanted with IVF fresh embryos in natural estrus, the Frozen group was transplanted with IVF frozen embryos after waiting for 3 weeks after exogenous gonadotropin treatment, and the NAC+VA group was transplanted with IVF fresh embryos after exogenous gonadotropin treatment. (B) and (C) Combined administration of NAC and VA can make the number of implantation sites and litter size of mice reach the level of the control group.
[0040] Figure 6 The health status of offspring born after the combined administration of NAC and VA is analyzed. (A) Transcriptome sequencing of the liver of offspring mice born from frozen and fresh embryo transplantation showed that the gene expression pattern of the frozen embryo group was partially changed, and the gene expression pattern of the offspring mice in the NAC combined with VA treatment group was closer to that of the control group. (B) The differentially downregulated genes in the frozen embryo group were mainly enriched in pathways such as NADH dehydrogenase activity, oxidative phosphorylation, and glucose metabolism.
[0041] Figure 7 The figure shows the effect of combined administration of NAC and VA on fetal development in precision sow batch production. The combined administration of NAC and VA can effectively alleviate the fetal development retardation caused by exogenous gonadotropin treatment. DETAILED DESCRIPTION
[0042] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.
[0043] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0044] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0045] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.
[0046] The present invention proposes a breeding method and application for reducing or eliminating the influence of exogenous gonadotropin on the reproductive performance of female livestock, which will be described in detail below.
[0047] method
[0048] In one aspect of the present invention, the present invention proposes a breeding method for reducing or eliminating the effect of exogenous gonadotropins on the reproductive performance of female livestock. According to an embodiment of the present invention, before treating female livestock with exogenous gonadotropins, N-acetylcysteine and vitamin A are fed to the female livestock; after feeding N-acetylcysteine and vitamin A, the ERα-FGF-pERK-cell cycle signaling pathway of the female livestock is inhibited to improve the uterine receptivity and pregnancy outcome of the female livestock after the exogenous gonadotropin treatment; the mass ratio of N-acetylcysteine and vitamin A is 0.5:1 to 8:1; the dosage of N-acetylcysteine is 60 mg / Kg BW / day to 200 mg / Kg BW / day, and the dosage of vitamin A is 25 mg / Kg BW / day to 120 mg / Kg BW / day.
[0049] According to the method of the embodiment of the present invention, by using NAC and VA in combination, the excessive activation of the ERα-FGF-pERK-cell cycle signaling pathway after exogenous gonadotropin treatment can be effectively inhibited, the effect of exogenous gonadotropin on the reproductive performance of female livestock can be reduced or eliminated, and the uterine receptivity and pregnancy outcomes, such as embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size, can be improved.
[0050] Furthermore, the inventors conducted in-depth research to obtain the mass ratio and respective dosage of NAC and VA, and especially found that by applying nearly 100 times more vitamin A than the vitamin A content in the conventional diet, it can achieve synergistic effect with NAC, and can further and better improve the effect of exogenous gonadotropin on the reproductive performance of female livestock. The method of the present invention has a wide range of application prospects, for example, it can be used in animal husbandry to achieve breeding regulation and management of livestock such as pigs, horses and cattle, and realize batch production, and has high application value.
[0051] According to an embodiment of the present invention, the mass ratio of N-acetylcysteine to vitamin A is 0.5:1 to 8:1, for example, it can be 0.5:1, 0.75:1, 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 8:1 or any two values as the range value formed by the endpoint values. Thus, the ERα-FGF-pERK-cell cycle signaling pathway can be better synergistically inhibited, and the uterine receptivity and pregnancy outcome after exogenous gonadotropin treatment can be improved, such as improving the embryo implantation rate, the fetal development status after implantation, the pregnancy rate and the litter size.
[0052] According to an embodiment of the present invention, the dosage of N-acetylcysteine is 60 mg / Kg BW / day to 200 mg / Kg BW / day, and the dosage of vitamin A is 25 mg / Kg BW / day to 120 mg / Kg BW / day. In some embodiments, the dosage of N-acetylcysteine fed is 60 mg / Kg BW / day, 80 mg / Kg BW / day, 100 mg / Kg BW / day, 120 mg / Kg BW / day, 150 mg / Kg BW / day, 180 mg / Kg BW / day, 200 mg / Kg BW / day, or any two values as the range formed by the endpoint values, and the dosage of vitamin A is 30 mg / Kg BW / day, 60 mg / Kg BW / day, 100 mg / Kg BW / day, 120 mg / Kg BW / day, or any two values as the range formed by the endpoint values, and "Kg BW" refers to the weight of female livestock in kilograms (Kg). Thus, it helps to better synergistically inhibit the ERα-FGF-pERK-cell cycle signaling pathway, improve uterine receptivity and pregnancy outcomes after exogenous gonadotropin treatment, such as improving embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size. In particular, by additionally applying nearly 100 times more vitamin A than in conventional diets, it can achieve synergistic effects with NAC, which can further and better improve the effects of exogenous gonadotropins on the reproductive performance of female livestock.
[0053] According to an embodiment of the present invention, oral administration of N-acetylcysteine and vitamin A is started 10 to 15 days before the treatment of female livestock with exogenous gonadotropins, and the administration is stopped at least until the first confirmation of pregnancy; or intraperitoneal administration of N-acetylcysteine and vitamin A is started 5 to 7 days before the treatment of female livestock with exogenous gonadotropins, and the administration is stopped at least until the first confirmation of pregnancy, or 3 to 4 days before the treatment of female livestock with exogenous gonadotropins, N-acetylcysteine and vitamin A are started via vaginal suppository, and the administration is stopped at least until the first confirmation of pregnancy. Specifically, pregnancy can be confirmed by conventional means such as B-ultrasound and pregnancy reaction. It can be understood that when pregnancy is first confirmed, NAC and VA can be stopped, or it can be stopped at any time during pregnancy, or it can be stopped when pregnancy is completed. Among them, stopping the administration when pregnancy is first confirmed can not only improve the uterine receptivity and pregnancy outcome after exogenous gonadotropin treatment, but also reduce the operational workload and cost caused by the additional administration of NAC and VA.
[0054] Herein, the term "female livestock" refers to female animals that are domesticated and raised by humans and whose reproduction can be artificially controlled, such as pigs, cattle, sheep, horses, donkeys, camels, rabbits, etc. According to an embodiment of the present invention, the female livestock is selected from gilts or multiparous sows.
[0055] According to an embodiment of the present invention, the improvement of uterine receptivity of female livestock after treatment with exogenous gonadotropins includes at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells; the pregnancy outcomes of female livestock after treatment with exogenous gonadotropins include at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size.
[0056] According to an embodiment of the present invention, the exogenous gonadotropin comprises at least one of the following: pregnant mare serum gonadotropin, equine chorionic gonadotropin, follicle-stimulating hormone, gonadotropin-releasing hormone and human chorionic gonadotropin.
[0057] According to an embodiment of the present invention, the method comprises: subjecting the female livestock to sequential sexual cycle synchronization treatment, exogenous gonadotropin treatment, ovulation induction treatment and insemination treatment; and before the exogenous gonadotropin treatment, feeding the female livestock with N-acetylcysteine and vitamin A. This helps to achieve batch production and improve batch production efficiency.
[0058] According to an embodiment of the present invention, the sexual cycle synchronization treatment includes: feeding allylgestaltin to gilts for 14 to 18 days or synchronous weaning of multiparous sows; the exogenous gonadotropin treatment includes: injecting exogenous gonadotropin to the female livestock 1.5 to 2 days after the sexual cycle synchronization treatment; the ovulation induction treatment includes: injecting ovulation-promoting drugs to the female livestock treated with the exogenous gonadotropin after an interval of 70 to 90 hours; the insemination treatment includes: performing the first insemination on the female livestock after the ovulation induction treatment after an interval of 20 to 28 hours, and then performing the second insemination after an interval of 14 to 16 hours.
[0059] In addition, the present invention proposes another breeding method for reducing or eliminating the influence of exogenous gonadotropin on the reproductive performance of female livestock, the method comprising: orally taking allylgestrogens for 17 to 19 days, wherein 80 to 110 mg / Kg BW of N-acetylcysteine and 80 to 110 mg / Kg BW of vitamin A are added to the feed respectively from the 5th to the 7th day until the end of the first pregnancy test, and the mass ratio of N-acetylcysteine to vitamin A is 0.5:1 to 2:1; after stopping the oral administration of allylgestrogens, injecting pregnant mare serum gonadotropin at an interval of 41 to 43 hours to induce synchronization of follicle development; after the injection of pregnant mare serum gonadotropin at an interval of 79 to 81 hours, injecting the ovulation-promoting drug gonadotropin, performing the first artificial insemination at an interval of 23 to 25 hours after the injection, and then performing the second artificial insemination at an interval of 15 to 17 hours. Therefore, the method of the present invention can effectively reduce or eliminate the reproductive performance of female livestock after treatment with exogenous gonadotropin, including their uterine receptivity and pregnancy outcomes, such as embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size, and N-acetylcysteine and vitamin A have a synergistic effect, and the application prospects are broad. For example, it can be used in animal husbandry to achieve breeding regulation and management of livestock such as pigs, horses and cattle, and realize batch production, and the application value is high.
[0060] application
[0061] In another aspect of the present invention, the present invention proposes the use of a combination of N-acetylcysteine and vitamin A in the preparation of medicine or feed. According to an embodiment of the present invention, the medicine or feed is used to improve the reproductive performance of subjects after exogenous gonadotropin treatment, and is used to inhibit the ERα-FGF-pERK-cell cycle signaling pathway to improve the uterine receptivity, pregnancy outcome and health status of offspring after the exogenous gonadotropin treatment of the subjects; the mass ratio of N-acetylcysteine to vitamin A is 0.5:1 to 8:1.
[0062] By using NAC and VA together and controlling the mass ratio of the two to 0.5:1-8:1, the excessive activation of the ERα-FGF-pERK-cell cycle signaling pathway after exogenous gonadotropin treatment can be effectively inhibited, the effects of exogenous gonadotropin on the reproductive performance of female livestock can be reduced or eliminated, and the uterine receptivity and pregnancy outcomes, such as embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size, can be improved. It can be applied in animal husbandry to realize batch production management.
[0063] As used herein, the term "subject" refers to any invertebrate or vertebrate subject, including but not limited to: humans and other primates, including non-human primates, such as chimpanzees and other apes and monkeys; livestock, such as cattle, sheep, pigs, goats and horses; domestic mammals, such as dogs and cats; laboratory animals, including rodents, such as mice, rats and guinea pigs; birds, including domestic, wild and game birds, such as chickens, turkeys and other chickens, ducks, geese, etc.; insects, nematodes, fish, amphibians and reptiles, etc., especially viviparous mammals of the subclass Theria, including humans, mice, pigs, cattle, sheep, horses, cats, dogs, etc. When it is a human, NAC and VA can be used to prepare assisted reproductive drugs to improve uterine receptivity and / or pregnancy outcomes and / or health status of offspring during assisted reproduction.
[0064] According to an embodiment of the present invention, the improvement of uterine receptivity after gonadotropin treatment includes at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells; the pregnancy outcome after gonadotropin treatment includes at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and number of offspring.
[0065] According to an embodiment of the present invention, the exogenous gonadotropin includes at least one of the following: pregnant mare serum gonadotropin (also referred to as "PMSG" in the present invention), equine chorionic gonadotropin (also referred to as "eCG" in the present invention), follicle-stimulating hormone (also referred to as "FSH" in the present invention), gonadotropin-releasing hormone (also referred to as "GnRH" in the present invention) and human chorionic gonadotropin (also referred to as "hCG" in the present invention).
[0066] According to an embodiment of the present invention, the administration methods of N-acetylcysteine combined with vitamin A are independently selected from oral administration, intragastric administration, intraperitoneal injection, intravenous injection, intravenous drip, intramuscular or subcutaneous injection.
[0067] According to an embodiment of the present invention, the dosage forms of N-acetylcysteine combined with vitamin A are independently selected from oral solution, injection, tablet, capsule, vaginal suppository or film.
[0068] In another aspect of the present invention, the present invention proposes the use of a combination of N-acetylcysteine and vitamin A in the preparation of a drug. According to an embodiment of the present invention, the drug is used for assisted reproduction, and is used to inhibit the ERα-FGF-pERK-cell cycle signaling pathway to improve the uterine receptivity, pregnancy outcome and health status of offspring after treatment with the exogenous gonadotropin; the mass ratio of N-acetylcysteine and vitamin A is 0.5:1 to 8:1. Thus, the drug according to the embodiment of the present invention can effectively reduce or eliminate uterine receptivity and pregnancy outcomes after exogenous gonadotropin, such as improving embryo implantation rate, fetal development status after implantation, pregnancy rate and health status of offspring, etc., which is of great significance in assisted reproductive technology.
[0069] According to an embodiment of the present invention, the assisted reproduction is selected from fresh embryo transfer. By administering NAC in combination with VA, the number of offspring born from fresh embryo transfer can be improved, and health problems of offspring caused by embryo freezing can be eliminated.
[0070] According to an embodiment of the present invention, the improvement of uterine receptivity after gonadotropin treatment includes at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells; the pregnancy outcome after gonadotropin treatment includes at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and number of offspring.
[0071] According to an embodiment of the present invention, the administration methods of the N-acetylcysteine combined with vitamin A are independently selected from oral administration, intragastric administration, intraperitoneal injection, intravenous injection, intravenous drip, intramuscular or subcutaneous injection.
[0072] According to an embodiment of the present invention, the dosage forms of the N-acetylcysteine combined with vitamin A are independently selected from oral liquid, injection, tablet, capsule, vaginal suppository or film.
[0073] In addition, the present invention proposes a method for assisted reproduction, improving the reproductive performance of female mammals, improving gonadotropin-induced decreased uterine receptivity and / or poor pregnancy outcomes, and a method for improving assisted reproductive uterine receptivity and / or pregnancy outcomes, the method comprising: administering the aforementioned N-acetylcysteine and vitamin A to a subject.
[0074] As used herein, the term "treatment" refers to obtaining a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug to an individual to treat, cure, alleviate, improve, mitigate or inhibit an individual's disease, including but not limited to administering a drug combination as described herein to an individual in need.
[0075] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0076] Example 1
[0077] Application of N-acetylcysteine combined with vitamin A to improve embryo implantation and litter size after gonadotropin treatment
[0078] 1. Experimental Animals
[0079] All experimental mice in this experiment were purchased from Beijing Sibeifu Company. The female mice were 8 weeks old and the male mice were 10 weeks old. After purchase, the experimental mice were kept in a light-controlled environment (12 hours of light: 12 hours of darkness). There were no special experimental requirements. All mice had free access to food and water, and the breeding environment was controlled at 20-24°C.
[0080] 2. Experimental Design
[0081] 2.1 Changes in molecular signaling pathways that affect decreased uterine receptivity after ovulation stimulation in mice
[0082] ICR female mice (SPF grade, 8 weeks old, 28-30g) were randomly divided into normal control group (CON) and superovulation stimulation group (eCG / hCG), with 10-18 mice in each group. The breeding environment temperature was 22℃, with 12-hour day and night alternation, and free access to food and water. After the animals were purchased, they first went through a 5-7 day adaptation period.
[0083] Control group (CON): Female 8-week-old ICR mice were used as the research subjects. They were naturally estrus and mated with sterilized male mice. After the plug was seen, they served as the control group. Then, on the 4th day after the plug was seen, when uterine receptivity was established, the mouse uterus was isolated and multiple signal molecules were detected.
[0084] Superovulation stimulation group (eCG / hCG): Female 8-week-old ICR mice were used as research subjects. They were injected with 10IU eCG at 18:00 in the afternoon and 10IU hCG at an interval of 48 hours to induce superovulation. Then they were caged together with ligated male mice. The vaginal plug was checked the next morning. The mice that had the plug were used as the superovulation stimulation group. Then, on the 4th day after the plug was seen, when uterine receptivity was established, the mouse uterus was isolated and multiple signal molecules were detected.
[0085] Endometrial samples from the CON group and eCG / hCG group on the fourth day of pregnancy were collected for molecular testing. The detection indicators included ERα, FGF family genes, FGF receptors, pERK, and epithelial cell proliferation signaling molecule Ki67 staining, in order to explore the molecular indicators of the effect of exogenous gonadotropins on the decreased uterine receptivity.
[0086] 2.2 Molecular regulatory effect of N-acetylcysteine combined with vitamin A in alleviating gonadotropin-induced decrease in uterine receptivity
[0087] 1) Experimental animal grouping
[0088] ICR female mice (SPF grade, 8 weeks old, 28-30g) were randomly divided into normal control group (CON), superovulation stimulation group (eCG / hCG), superovulation stimulation and BGJ398 group (eCG / hCG+BGJ398), superovulation stimulation and NAC alone group (eCG / hCG+NAC), superovulation stimulation and VA alone group (eCG / hCG+VA), superovulation stimulation and NAC, VA combined group (eCG / hCG+NAC+VA), 10-18 mice in each group. The temperature of the breeding environment was 22℃, with 12-hour day and night alternation, and free access to food and water. After the animals were purchased, they first went through a 5-7 day adaptation period.
[0089] Control group (CON): Female 8-week-old ICR mice were used as the research subjects. They were naturally estrus and mated with sterilized male mice as the control group. Then, on the 4th day after plugging, when uterine receptivity was established, the mouse uterus was isolated and multiple signal molecules were detected.
[0090] Superovulation stimulation group (eCG / hCG): Female 8-week-old ICR mice were used as research subjects. They were injected with 10IU eCG at 18:00 in the afternoon and 10IU hCG at an interval of 48 hours to induce superovulation. Then they were caged together with ligated male mice. The vaginal plug was checked the next morning. The mice that had the plug were used as the superovulation stimulation group. Then, on the 4th day after the plug was seen, when uterine receptivity was established, the mouse uterus was isolated and multiple signal molecules were detected.
[0091] Superovulation stimulation and BGJ398 group (eCG / hCG+BGJ398): Female 8-week-old ICR mice were used as research subjects and injected with 10 IU eCG and PMSG to induce superovulation. On the third day after the appearance of the plug, the mice were injected with 5 μl of 100 μM FGF receptor inhibitor BGJ398 inhibitor through the uterine horn. Then on the fourth day after the appearance of the plug, when uterine receptivity was established, the mouse uterus was isolated for detection of multiple signal molecules.
[0092] Superovulation stimulation and NAC alone group (eCG / hCG+NAC): Female 8-week-old ICR mice were used as the research subjects. On the basis of the superovulation stimulation group (eCG / hCG) treatment, each mouse began to receive daily intraperitoneal injections of 200 mg / Kg BW of NAC 5 days before the injection of eCG. Then, on the 4th day after the appearance of the thrombus, when uterine receptivity was established, the mouse uterus was isolated for detection of multiple signal molecules.
[0093] Superovulation stimulation and VA alone group (eCG / hCG+VA): Female 8-week-old ICR mice were used as the research subjects. On the basis of the superovulation stimulation group (eCG / hCG) treatment, each mouse began to receive daily intraperitoneal injections of 200 mg / Kg BW of VA 5 days before the injection of eCG / hCG. Then, on the 4th day after the appearance of the thrombus, when uterine receptivity was established, the mouse uterus was isolated for detection of multiple signal molecules.
[0094] Superovulation stimulation combined with NAC and VA (eCG / hCG+NAC+VA): Female 8-week-old ICR mice were used as the research subjects. On the basis of the superovulation stimulation group (eCG / hCG) treatment, 5 days before the injection of eCG, each mouse began to be intraperitoneally injected with a mixture of 100 mg / Kg BW of NAC and 100 mg / Kg BW of VA every day. Then, on the 4th day after the appearance of the thrombus, when the uterine receptivity was established, the mouse uterus was isolated for the detection of multiple signal molecules.
[0095] The time of single administration and combined administration is as shown in the figure Figure 2 shown.
[0096] 2) Molecular marker detection
[0097] Endometrial samples on the fourth day of pregnancy were collected from the CON group, eCG / hCG group, eCG / hCG+BGJ398 group, eCG / hCG+NAC group, eCG / hCG+VA group, and eCG / hCG+NAC+VA group of mice for molecular testing. The detection indicators included ERα, pERK and other key molecules involved in the decreased uterine receptivity induced by exogenous gonadotropin.
[0098] 2.3 Application of N-acetylcysteine combined with vitamin A in alleviating reproductive performance of mice after gonadotropin treatment
[0099] 1) Experimental animal grouping
[0100] ICR female mice (SPF grade, 8 weeks old, 28-30g) were randomly divided into normal control group (CON), superovulation stimulation group (eCG / hCG), superovulation stimulation and BGJ398 group (eCG / hCG+BGJ398), superovulation stimulation and NAC alone group (eCG / hCG+NAC), superovulation stimulation and VA alone group (eCG / hCG+VA), superovulation stimulation and NAC, VA combined group (eCG / hCG+NAC+VA), 10-18 mice in each group. The temperature of the breeding environment was 22℃, with 12-hour day and night alternation, and free access to food and water. After the animals were purchased, they first went through a 5-7 day adaptation period.
[0101] Control group (CON): Female 8-week-old ICR mice were used as the research subjects. They were mated with sterilized male mice after natural estrus and served as the control group recipient mice. Embryo transplantation was then performed on the 4th day after thrombosis.
[0102] Superovulation stimulation group (eCG / hCG): Female 8-week-old ICR mice were used as research subjects. They were injected with 10IU eCG at 18:00 in the afternoon and 10IU hCG at an interval of 48 hours to induce superovulation. Then they were caged together with sterilized male mice. The vaginal plug was checked the next morning. After the plug was found, they were used as the recipients of the superovulation stimulation group. Embryo transfer was then performed on the 4th day after the plug was found.
[0103] Superovulation stimulation and BGJ398 group (eCG / hCG+BGJ398): Female 8-week-old ICR mice were used as research subjects and injected with 10 IU eCG and PMSG to induce superovulation. On the third day of pregnancy, the mice were injected with 5 μl of 100 μM FGF receptor inhibitor BGJ398 inhibitor through the uterine horn, and then embryo transfer was performed on the fourth day after the appearance of the thrombus.
[0104] Superovulation stimulation and NAC alone group (eCG / hCG+NAC): Female 8-week-old ICR mice were used as the research subjects. On the basis of the superovulation stimulation group (eCG / hCG) treatment, each mouse began to receive daily intraperitoneal injections of 200 mg / Kg BW of NAC 5 days before eCG injection, and then embryo transfer was performed on the 4th day after the appearance of the thrombus, and the injection was continued until the 10th day of pregnancy.
[0105] Superovulation stimulation and VA alone group (eCG / hCG+VA): Female 8-week-old ICR mice were used as the research subjects. On the basis of the superovulation stimulation group (eCG / hCG) treatment, each mouse began to receive daily intraperitoneal injections of 200 mg / Kg BW of VA 5 days before the injection of eCG / hCG, and then embryo transfer was performed on the 4th day after the appearance of the thrombus, and the injection was continued until the 10th day of pregnancy.
[0106] Superovulation stimulation combined with NAC and VA (eCG / hCG+NAC+VA): Female 8-week-old ICR mice were used as the research subjects. On the basis of the superovulation stimulation group (eCG / hCG) treatment, 5 days before the injection of eCG, each mouse began to be intraperitoneally injected with a mixture of 100 mg / Kg BW of NAC and 100 mg / Kg BW of VA every day, and then embryo transfer was performed on the 4th day after the appearance of the thrombus, and the injection was continued until the 10th day of pregnancy.
[0107] The time of single administration and combined administration is as shown in the figure Figure 2 shown.
[0108] 2) Embryo transfer experiment
[0109] The mice in the CON group, eCG / hCG group, eCG / hCG+BGJ398 group, eCG / hCG+NAC group, eCG / hCG+VA group, and eCG / hCG+NAC+VA group were mated with ligated male mice, and the plugs were picked up at around 8 o'clock the next morning. The pseudo-pregnant female mice with plugs were used for transplantation. The day of plugs was counted as day 1, and day 4 was the date of blastocyst transplantation. Six IVF blastocysts were transferred into each uterine horn of each mouse, and then placed in the animal room for normal feeding.
[0110] 3)Embryo implantation statistics
[0111] Embryo transplantation was performed on the 4th day of pregnancy in the CON group, eCG / hCG group, eCG / hCG+BGJ398 group, eCG / hCG+NAC group, eCG / hCG+VA group, and eCG / hCG+NAC+VA group of mice, respectively; and the embryo implantation sites were counted by orbital injection of Chicago blue on the 5th day of pregnancy.
[0112] 4) Litter size statistics
[0113] Embryo transplantation was performed on the fourth day of pregnancy in the CON, eCG / hCG, eCG / hCG+BGJ398, eCG / hCG+NAC, eCG / hCG+VA, and eCG / hCG+NAC+VA groups of mice. The mice were then placed in the animal room and raised normally. On the day of delivery, the number of live pups born per litter was counted.
[0114] 3. Experimental results
[0115] Molecular detection experiments have found that eCG / hCG induced ovulation treatment leads to overactivation of the endometrial "ERα-FGF-pERK-cell cycle" signaling pathway ( Figure 1 ), which in turn causes abnormal uterine receptivity and ultimately leads to embryo implantation failure. Therefore, the present invention uses "inhibiting excessive activation of the ERα-FGF-pERK-cell cycle signaling pathway" as a new target for improving the side effects of eCG / hCG on the endometrium. The present invention uses the FGF receptor inhibitor BGJ398, NAC (nitroacetylcysteine) and VA (vitamin A) selected in the early drug screening as candidate drugs. Further signal molecule detection found that VA can significantly inhibit the expression of ERa, while BGJ398 and NAC can significantly inhibit the hyperphosphorylation of pERK, and the combination of NAC and VA has a synergistic effect in inhibiting the ERα-FGF-pERK signaling pathway ( Figure 3 ).
[0116] 2.3 Application of N-acetylcysteine combined with vitamin A in alleviating reproductive performance of mice after gonadotropin treatment
[0117] 1) Experimental animal grouping
[0118] ICR female mice (SPF grade, 8 weeks old, 28-30g) were randomly divided into groups, and the exogenous gonadotropin treatment group was used as the control group (CON); BGJ398 group (BGJ398), NAC alone group (NAC), VA alone group (VA), VC alone group (VC), melatonin (MT) alone group (MT), different ratios of NAC and VA combined group (NAC+VA), NAC and Vc combined group (NAC+Vc), VA and MT combined group (VA+MT) were treated with exogenous gonadotropin, and each group had 10-18 mice. The temperature of the breeding environment was 22℃, with 12 hours of day and night alternation, and free access to food and water. After the animals were purchased, they first went through a 5-7 day adaptation period.
[0119] The specific processing is as follows:
[0120] Female 8-week-old ICR mice were used as the research subjects. They were injected with 10 IU eCG at 18:00 in the afternoon, and 10 IU hCG was injected at 48 hours intervals to induce superovulation. Then they were caged with ligated male mice. The vaginal plug was checked the next morning. After the plug was found, it was used as the recipient after exogenous gonadotropin treatment. Then, embryo transfer was performed on the 4th day after the plug was found. The dosage and administration time of other drugs in each group are shown in Table 1. The time of single administration and combined administration is as shown in the figure Figure 2 shown.
[0121] Table 1. Drug dosage and administration time for different groups
[0122]
[0123] 2) Statistics of embryo implantation and litter size
[0124] On the second day after embryo transfer, each group of mice (5-9 mice / group) was injected with Chicago blue via the eye socket to count the embryo implantation sites. The remaining groups of mice (5-9 mice / group) were placed in the animal room for normal feeding, and the number of live pups born was counted on the day of delivery.
[0125] 3) Experimental results
[0126] The present invention further tested the application of N-acetylcysteine combined with vitamin A in alleviating the reproductive performance of mice after gonadotropin treatment. The results showed that the number of implantation sites in the BGJ398 group (uterine horn injection of FGF receptor inhibitor BGJ398) mice on the 5th day after pregnancy was significantly higher than that in the control group ( Figure 4 However, tracking the data of pregnancy and litter size revealed that BGJ398, as a small molecule inhibitor, was highly toxic to fetal development, causing post-implantation fetal developmental regression ( Figure 4 B and C in the figure). VC is an analogue of VA, and MT is melatonin, which also has antioxidant effects and promotes reproduction. However, their effects are not good when acting alone or in synergy with NAC / VA.
[0127] Injection of 200mg / Kg BW of NAC and 200mg / Kg BW of VA alone increased the number of implantation sites and litter size to a certain extent in mice ( Figure 4A and B in the figure). When NAC and VA were used in combination at a ratio of 1:1, the number of implantation sites and litter size of mice was significantly higher than that of the control group, and significantly higher than that of the group that was given NAC or VA alone; when NAC and VA were used in combination at a ratio of 0.1:1, the number of implantation sites and litter size of mice was significantly lower than that of the control group; when NAC and VA were used in combination at a ratio of 9:1, the number of implantation sites and litter size of mice was not significantly different from that of the group that was given NAC or VA alone. This further indicates that the appropriate ratio of NAC and VA (0.5:1 to 8:1) has a synergistic effect in reducing or eliminating the side effects of exogenous gonadotropins and improving pregnancy outcomes.
[0128] Example 2
[0129] Application of N-acetylcysteine combined with vitamin A to improve the health status of offspring born after frozen embryo transfer
[0130] 1. Experimental design ideas
[0131] In the field of assisted reproduction, since exogenous gonadotropins cause a decrease in uterine receptivity, it is not appropriate to directly use fresh embryos for transplantation. Fresh embryos are often first cryopreserved, and then the frozen embryos are transplanted after the side effects caused by exogenous gonadotropins are alleviated. However, cryopreservation of embryos has a certain impact on the health of embryos and newborns. For this reason, the present invention combines N-acetylcysteine with vitamin A to improve the reproductive performance of mice after gonadotropin treatment, and combines fresh embryos to help the health of newborn pups.
[0132] 2. Experimental animals and groups
[0133] ICR female mice (SPF grade, 8 weeks old, 28-30g) were randomly divided into groups, including the IVF fresh embryos transferred into the natural estrus cycle recipient group (CON group), the IVF frozen embryos transferred into the interval cycle recipient group (Frozen group), and the IVF fresh embryos transferred into the ovarian stimulation and NAC combined with VA recipient group (NAC+VA group) ( Figure 5 A), 10-18 animals per group. The temperature of the breeding environment is 22°C, with a 12-hour day and night cycle, and free access to food and water. After the animals are purchased, they first undergo a 5-7 day adaptation period.
[0134] CON group: Female 8-week-old ICR mice were used as the research subjects. After natural estrus, they were mated with sterilized male mice and served as the control group recipient mice. Subsequently, IVF fresh embryo transfer was performed on the 4th day after thrombosis.
[0135] Frozen group: Female 8-week-old ICR mice were used as research subjects. They were injected with 10 IU eCG at 18:00 in the afternoon, and then injected with 10 IU hCG at an interval of 48 hours to induce superovulation. They were then left alone for 3 weeks and mated with sterilized male mice after natural estrus again. The mice served as recipient mice in the Frozen group, and IVF frozen embryo transplantation was performed on the 4th day after thrombosis.
[0136] NAC+VA group: Female 8-week-old ICR mice were used as the research subjects. On the basis of the superovulation stimulation group (eCG / hCG) treatment, each mouse began to receive daily intraperitoneal injections of a mixture of 100 mg / KgBW of NAC and 100 mg / KgBW of VA 5 days before the injection of eCG. Subsequently, IVF fresh embryo transfer was performed on the 4th day after the appearance of the thrombus, and the NAC+VA mixture was continuously injected until the 10th day of pregnancy.
[0137] 3.Embryo implantation and litter size statistics
[0138] Embryo transplantation was performed on the fourth day of pregnancy in the CON, Frozen, and NAC+VA groups of mice. Chicago blue was injected into the eye sockets on the fifth day of pregnancy, and the embryo implantation sites were counted.
[0139] Embryo transplantation was performed on the fourth day of pregnancy in the CON, Frozen, and NAC+VA groups of mice. The mice were then placed in the animal room for normal feeding. On the day of delivery, the number of live pups born was counted.
[0140] 4. Transcriptome Analysis of Liver Tissues of Newborn Mice
[0141] Embryo transplantation was performed on the fourth day of pregnancy in the CON, Frozen, and NAC+VA groups of mice, and they were then placed in the animal room for normal feeding. On the day of delivery, the liver tissue of the newborn mice was isolated and used for transcriptome sequencing, and the transcriptome data were then subjected to GO and KEGG analysis.
[0142] 5. Results Analysis
[0143] The results showed that there was no significant difference in the number of embryo implantation and the number of live piglets born among the CON, Frozen, and NAC+VA groups ( Figure 5 B and C in Example 1) show that NAC combined with VA can effectively alleviate the decline in uterine receptivity induced by exogenous gonadotropin. Further transcriptome sequencing of the liver of offspring mice born from frozen and fresh embryo transplantation revealed that the gene expression pattern of the frozen embryo group was partially changed, and the gene expression pattern of the offspring mice in the NAC combined with VA treatment group was closer to that of the control group ( Figure 6 The down-regulated differentially expressed genes in the frozen embryo group were mainly enriched in pathways such as NADH dehydrogenase activity, oxidative phosphorylation, and glucose metabolism ( Figure 6B), which indicates that the liver metabolism of mice born from frozen embryo transplantation is abnormal. The combined administration of NAC and VA in an appropriate ratio (0.5:1-8:1) can improve the number of offspring born from fresh embryo transplantation without affecting the health of the offspring.
[0144] Example 3
[0145] Application of N-acetylcysteine combined with vitamin A in precision sow batch production
[0146] 1. Experimental Animals
[0147] All experimental sows in this experiment were provided by Henan Xinda Animal Husbandry Co., Ltd., and gilts aged 200-250 days and weighing 120-140 kg were selected for the experiment.
[0148] 2. Sow batch experimental design
[0149] Effects of 2.1N-acetylcysteine combined with vitamin A on embryonic development in precision sow batch production
[0150] 1) Experimental animal grouping and handling procedures
[0151] Gilts aged 200-250 days and weighing 120-140 kg were selected for the experiment and divided into five groups: CON group, eCG / GnRH group, eCG / GnRH+NAC group, eCG / GnRH+VA group, and eCG / GnRH+NAC+VA group, with 6-8 gilts in each group.
[0152] The technical process for batch production of gilts in the eCG / GnRH group (i.e., the precision batch production plan for sows) is as follows: 1) Sexual cycle synchronization treatment: sows take allylgestaltenes orally for 18 days; 2) After sexual cycle synchronization treatment, exogenous gonadotropin eCG is injected at an interval of 42 hours to induce synchronization of follicle development; 3) 80 hours after eCG injection, the ovulation-inducing drug gonadorelin (GnRH) is injected, and the first artificial insemination is performed 24 hours after the injection, and the second artificial insemination is performed 16 hours after the injection.
[0153] Based on the batch production technology process of gilts in the eCG / GnRH group, the three groups of eCG / GnRH+NAC, eCG / GnRH+VA and eCG / GnRH+NAC+VA added 200mg / KgBW of NAC, 200mg / KgBW of VA and a combination of NAC (100mg / KgBW) and VA (100mg / KgBW) to the feed every day 14 days before the injection of eCG until the end of the first pregnancy check (30-32 days of pregnancy).
[0154] The technical process of batch production of reserve sows in the CON group (i.e., simplified batch production plan for sows) is as follows: 1) Sexual cycle synchronization treatment: sows are given oral administration of allylgestaltin for 18 days; 2) Then they come into estrus naturally, and the estrus of the sows is confirmed by artificial estrus checking; 3) The first artificial insemination is performed after the sow comes into estrus, and the second artificial insemination is performed after an interval of 16 hours.
[0155] 2) Detect the fetal development and birth status after embryo implantation
[0156] On the 19th day of pregnancy, 6 to 8 sows were slaughtered in each group, and the embryos were recovered by flushing the uterine horns of the pregnant sows. The embryonic development status of the different treatment groups was compared.
[0157] 3) Experimental results
[0158] The results are as follows Figure 7 As shown in the data, compared with the simplified sow batch production, the precision sow batch production caused delayed embryo development due to exogenous gonadotropin treatment. The combined administration of NAC and VA significantly improved the developmental state of the embryo, which was closer to the developmental state of the embryo without exogenous gonadotropin treatment (control group).
[0159] Effects of 2.2N-acetylcysteine combined with vitamin A on reproductive performance of sows in precision sow batch production
[0160] 1) Experimental animal grouping and handling procedures
[0161] Gilts aged 200-250 days and weighing 120-140kg were selected for the experiment and divided into precision sow batch production (CON) group, precision sow batch production supplemented with NAC (NAC) group, precision sow batch production supplemented with VA (VA) group, precision sow batch production with combined administration of NAC and VA (NAC+VA1:1) group, precision sow batch production with combined administration of NAC and VA (NAC+VA 0.1:1) group, and precision sow batch production with combined administration of NAC and VA (NAC+VA9:1) group, with 48-55 sows in each group.
[0162] The technical process of batch production of replacement sows in the CON group (i.e., precision batch production program) is as follows: 1) Sexual cycle synchronization treatment: sows are given oral administration of allylgestaltin for 18 days; 2) After sexual cycle synchronization treatment, exogenous gonadotropin eCG is injected at an interval of 42 hours to induce synchronization of follicle development; 3) After eCG injection, the ovulation-inducing drug gonadorelin (GnRH) is injected at an interval of 80 hours, and the first artificial insemination is performed 24 hours after injection, and the second artificial insemination is performed 16 hours after injection. Pregnancy examination is then performed, and the sows are raised normally until delivery.
[0163] The three groups of NAC, VA, and NAC+VA were based on the batch production technology of gilts in the CON group. 14 days before the injection of eCG, 200 mg / Kg BW of NAC, 200 mg / Kg BW of VA, NAC (100 mg / Kg BW) and VA (100 mg / Kg BW) were added to the feed every day, NAC (20 mg / Kg BW) and VA (180 mg / Kg BW) were added together, and NAC (180 mg / Kg BW) and VA (20 mg / Kg BW) were added together until the end of the first pregnancy test (gestational day 30-32). Then they were raised normally until delivery.
[0164] 2) Statistics on birthing
[0165] Through pregnancy examination, the pregnancy rate of sows was calculated; during delivery, the farrowing rate of sows was calculated. The pregnancy rate and farrowing rate of sows in different treatment groups were calculated as follows:
[0166] Sow pregnancy rate = number of pregnant sows / number of bred sows × 100%
[0167] Sow farrowing rate = number of farrowing sows / number of bred sows × 100%
[0168] 3) Experimental results
[0169] As can be seen from Table 2, compared with the pregnancy rate and farrowing rate of sows in precision sow batch production, single supplementation of NAC or VA can significantly improve the pregnancy rate and farrowing rate of sows; when NAC and VA were co-administered at a ratio of 1:1, the pregnancy rate and farrowing rate of sows were significantly higher than those of the group supplemented with NAC or VA alone; however, when NAC and VA were co-administered at a ratio of 0.1:1, the pregnancy rate and farrowing rate of sows were lower than those of the control group; when NAC and VA were co-administered at a ratio of 9:1, the pregnancy rate and farrowing rate of sows were not significantly different from those of the group supplemented with NAC or VA alone. Therefore, NAC and VA in appropriate ratios have a synergistic effect (Table 2).
[0170] Table 2: Effects of NAC combined with VA on pregnancy rate and farrowing rate in precision sow batch production
[0171]
[0172] Note: Different lowercase letters indicate significant differences, P<0.05.
[0173] Advantages of the present invention
[0174] In view of the problems of low pregnancy rate and decreased delivery rate caused by exogenous gonadotropin, the present invention combines NAC with VA to establish a method for improving the decreased uterine receptivity and poor pregnancy outcomes induced by exogenous gonadotropin. Compared with the prior art, the present invention significantly improves the pregnancy rate and delivery rate after exogenous gonadotropin treatment under the premise of side effects caused by exogenous gonadotropin treatment. The present invention has great value for large-scale promotion of sow precision batch production and improvement of assisted reproduction effect in my country.
[0175] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
[0176] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A breeding method for reducing or eliminating the effect of exogenous gonadotropin on the reproductive performance of female livestock, characterized in that: include: Prior to treating the female livestock with exogenous gonadotropin, feeding the female livestock with N-acetylcysteine and vitamin A; After being fed with N-acetylcysteine and vitamin A, the ERα-FGF-pERK-cell cycle signaling pathway of the female livestock is inhibited, so as to improve the uterine receptivity and pregnancy outcome of the female livestock after being treated with the exogenous gonadotropin; The mass ratio of N-acetylcysteine to vitamin A is 0.5:1 to 8:1; The dosage of N-acetylcysteine is 60 mg / Kg BW / day to 200 mg / Kg BW / day, and the dosage of vitamin A is 25 mg / Kg BW / day to 120 mg / Kg BW / day.
2. The method according to claim 1, characterized in that Oral administration of N-acetylcysteine and vitamin A starting 10 to 15 days before treatment of female livestock with exogenous gonadotropins and discontinued until at least the time pregnancy is first confirmed; or N-acetylcysteine and vitamin A should be administered intraperitoneally starting 5 to 7 days before exogenous gonadotropin treatment of females and continuing until at least the time pregnancy is first confirmed, or N-acetylcysteine and vitamin A are administered via vaginal suppository starting 3 to 4 days before treatment of female livestock with exogenous gonadotropins and are discontinued at least until pregnancy is first confirmed.
3. The method according to claim 1, characterized in that The female livestock is selected from gilts or multiparous sows; The exogenous gonadotropin includes at least one of the following: pregnant mare serum gonadotropin, equine chorionic gonadotropin, follicle-stimulating hormone, gonadotropin-releasing hormone and human chorionic gonadotropin; The improving uterine receptivity of female livestock after treatment with exogenous gonadotropin comprises at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells; The pregnancy outcomes of female livestock after the exogenous gonadotropin treatment include at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size.
4. The method according to claim 1, characterized in that: The method comprises: subjecting the female livestock to a sexual cycle synchronization treatment, an exogenous gonadotropin treatment, an ovulation induction treatment and an insemination treatment in sequence; Prior to the exogenous gonadotropin treatment, the female livestock were fed N-acetylcysteine and vitamin A.
5. The method according to claim 4, characterized in that The sexual cycle synchronization treatment includes: feeding allylgestaltenes to gilts for 14 to 18 days or synchronous weaning of multiparous sows; The exogenous gonadotropin treatment comprises: injecting exogenous gonadotropin into the female livestock 1.5 to 2 days after the sexual cycle synchronization treatment; The ovulation induction treatment comprises: injecting an ovulation-inducing drug into the female livestock treated with the exogenous gonadotropin after an interval of 70 to 90 hours; The insemination treatment comprises: performing a first insemination on the female livestock after the ovulation induction treatment after an interval of 20 to 28 hours, and then performing a second insemination after an interval of 14 to 16 hours.
6. A breeding method for reducing or eliminating the effect of exogenous gonadotropin on the reproductive performance of female livestock, characterized in that: include: The gilts were orally administered allylprogesterone for 17 to 19 days, during which 80 to 110 mg / Kg BW of N-acetylcysteine and 80 to 110 mg / Kg BW of vitamin A were added to the feed from the 5th to 7th day until the first pregnancy test was completed, with the mass ratio of N-acetylcysteine to vitamin A being 0.5:1 to 2:1; after stopping oral administration of allylprogesterone, pregnant mare serum gonadotropin was injected at an interval of 41 to 43 hours to induce synchronization of follicular development; after the injection of pregnant mare serum gonadotropin, the ovulation-inducing drug gonadotropin was injected at an interval of 79 to 81 hours, and the first artificial insemination was performed at an interval of 23 to 25 hours after the injection, and the second artificial insemination was performed at an interval of 15 to 17 hours thereafter.
7. The use of a combination of N-acetylcysteine and vitamin A in the preparation of medicine or feed, characterized in that: The drug or feed is used to improve the reproductive performance of subjects after treatment with exogenous gonadotropin, and is used to inhibit the ERα-FGF-pERK-cell cycle signaling pathway to improve the uterine receptivity, pregnancy outcome and health status of offspring after treatment with exogenous gonadotropin; The mass ratio of the N-acetylcysteine to vitamin A is 0.5:1 to 8:
1.
8. The use according to claim 7, characterized in that: The improving the uterine receptivity of the subject after the treatment with exogenous gonadotropin comprises at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells; The pregnancy outcomes of the subjects after the exogenous gonadotropin treatment include at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and litter size; The exogenous gonadotropin includes at least one of the following: pregnant mare serum gonadotropin, equine chorionic gonadotropin, follicle-stimulating hormone, gonadotropin-releasing hormone and human chorionic gonadotropin; The administration methods of the N-acetylcysteine combined with vitamin A are independently selected from oral administration, intragastric administration, intraperitoneal injection, intravenous injection, intravenous drip, intramuscular or subcutaneous injection; The dosage forms of the N-acetylcysteine combined with vitamin A are independently selected from oral liquid, injection, tablet, capsule, vaginal suppository or film.
9. The use of a combination of N-acetylcysteine and vitamin A in the preparation of a medicine, characterized in that: The drug is used for assisted reproduction and is used to inhibit the ERα-FGF-pERK-cell cycle signaling pathway to improve the uterine receptivity, pregnancy outcome and health status of offspring after treatment with exogenous gonadotropin in subjects; The mass ratio of the N-acetylcysteine to vitamin A is 0.5:1 to 8:
1.
10. The use according to claim 9, characterized in that: The assisted reproduction is selected from fresh embryo transfer; The improvement of uterine receptivity after gonadotropin treatment includes at least one of the following: inhibiting the ERα-FGF-pERK-cell cycle signaling pathway, inhibiting the mitotic cycle of endometrial epithelial cells; The pregnancy outcomes after gonadotropin treatment include at least one of the following: embryo implantation rate, fetal development status after implantation, pregnancy rate and number of offspring; The administration methods of the N-acetylcysteine combined with vitamin A are independently selected from oral administration, intragastric administration, intraperitoneal injection, intravenous injection, intravenous drip, intramuscular or subcutaneous injection; The dosage forms of the N-acetylcysteine combined with vitamin A are independently selected from oral liquid, injection, tablet, capsule, vaginal suppository or film.
Citation Information
Patent Citations
Method for increasing number of early embryo implantation in goat and litter size
CN109042515A
Composition Useful for Promoting Female Fertility
US20160303164A1
